#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	7068	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2648	627.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1627	1627	C	894	C,A,G,T	774,8,3,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	11764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4167	662.4	0	.	n	.	0	T695C	SNP	695	695	T	1376	1376	C	899	C,A,T,G	790,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	11764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4167	662.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2652	2652	C	807	C,A,T,G	712,4,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	11764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4167	662.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2726	2726	A	771	A,C,T	694,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	11764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4167	662.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3278	3278	C	791	C,T,A	716,3,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	11764	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4167	662.4	0	HET	.	.	.	A1638G,T	.	1638	1638	A	2319	2319	A	814	A,G,T	362,395,1	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	522	folP	855	855	100.0	folP.l15.c4.ctg.1	1949	62.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1265	1267	AGC	81;80;78	A;G;C	68;69;66	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1238	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	73.3	1	SNP	p	S91F	1	.	.	271	273	TTC	867	869	TTC	91;92;92	T;T;C,A	77;78;81,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1238	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	73.3	1	SNP	p	D95G	1	.	.	283	285	GGC	879	881	GGC	98;99;99	G,A;G;C,A	86,1;88;85,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1238	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	73.3	1	SNP	p	G95N	0	.	.	283	285	GGC	879	881	GGC	98;99;99	G,A;G;C,A	86,1;88;85,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	356	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1634	50.9	1	SNP	p	G45D	0	.	.	133	135	GGC	587	589	GGC	106;108;108	G;G,T;C	87;92,1;90	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	292	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1393	49.8	0	.	n	.	0	A197.	DEL	197	197	A	733	733	A	89	A	79	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1340	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3118	100.1	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	90;90;90	G;A,C,G;C,A	67;52,2,1;63,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1340	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3118	100.1	1	SNP	p	R87W	0	.	.	259	261	CGT	581	583	CGT	90;91;94	C;G;T	75;62;74	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1340	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3118	100.1	1	SNP	p	R87I	0	.	.	259	261	CGT	581	583	CGT	90;91;94	C;G;T	75;62;74	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1340	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3118	100.1	1	SNP	p	S87R	1	.	.	259	261	CGT	581	583	CGT	90;91;94	C;G;T	75;62;74	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1340	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3118	100.1	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	94;96;98	T,C;C;C	78,1;82;87	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1102	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3306	79.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1897	1899	GGC	66;66;67	G;G,A;C,G,A	52;54,1;51,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	A311V	0	.	.	931	933	GCC	1586	1588	GCC	154;158;158	G,A,C;C;C,A,T	139,1,1;144;142,1,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	I312M	1	.	.	934	936	ATG	1589	1591	ATG	158;160;160	A;T,G;G,T	143;142,4;144,2	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	V316T	1	.	.	946	948	ACC	1601	1603	ACC	159;159;158	A,C,T,G;C,A;C	137,2,1,1;145,1;145	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	T316P	0	.	.	946	948	ACC	1601	1603	ACC	159;159;158	A,C,T,G;C,A;C	137,2,1,1;145,1;145	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	2102	2104	ACC	141;141;139	A;C,A;C	117;116,1;122	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2156	2158	GCG	137;137;137	G;C,T;G,A	113;104,1;116,2	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2156	2158	GCG	137;137;137	G;C,T;G,A	113;104,1;116,2	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2279	2281	GGT	94;92;92	G,T;G,T,C;T,C	85,3;78,5,1;85,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2288	2290	AGC	84;84;86	A,G;G;C,G,A	58,2;64;58,5,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1206	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2611	106.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2306	2308	CCG	74;74;74	C,T;C;G,C,T	61,1;58;57,6,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1746	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3545	112.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1897	1899	CCG	136;136;136	C,G,T;C,T;G,C,T,A	104,4,1;118,1;95,6,1,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	592	porA	1146	1146	99.91	porA.l6.c4.ctg.1	2262	61.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	784	784	C	56	C,G,A	35,1,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	864	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1834	108.1	0	.	p	.	0	G252E	NONSYN	754	756	GGA	1016	1018	GAA	112;112;110	G;A;A,G	101;101;98,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	864	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1834	108.1	1	SNP	p	G120K	1	.	.	358	360	AAG	620	622	AAG	150;150;152	A,T;A;G,T	133,1;135;137,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	864	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1834	108.1	1	SNP	p	A121N	1	.	.	361	363	AAC	623	625	AAC	152;151;151	A,G;A;C,A	136,1;135;133,2	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	864	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1834	108.1	1	SNP	p	N121D	0	.	.	361	363	AAC	623	625	AAC	152;151;151	A,G;A;C,A	136,1;135;133,2	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3468	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4937	165.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	400	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1457	66.2	1	SNP	p	V57M	1	.	.	169	171	ATG	784	786	ATG	138;137;137	A;T;G	126;128;128	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
